Exelixis (EXEL) Share-based Compensation (2010 - 2026)
Exelixis (EXEL) recorded quarterly Share-based Compensation of $29.0 million in Q2 2026, up 44.55% quarter-over-quarter from $20.1 million in Q1 2026, and up 12.03% on a YoY basis from $25.9 million in Q2 2025.
Exelixis (EXEL) Share-based Compensation (2010 - 2026) Analysis & Trends
Exelixis' Share-based Compensation history runs 17 years deep, the most recent figure standing at $29.0 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 12.03% year-over-year to $29.0 million; the TTM figure through Apr 2026 stood at $116.1 million (up 15.35% YoY), while the FY2026 annual figure was $113.0 million, up 20.4% from the prior year.
- Share-based Compensation was $29.0 million for Q2 2026 at Exelixis, up from $20.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $40.5 million in Q3 2023 to a low of $16.7 million in Q1 2023.
- Historically, Share-based Compensation has averaged $26.5 million across 5 years, with a median of $25.4 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation slumped 43.12% in 2024, then jumped 42.27% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $25.9 million in 2022, then slipped by 5.99% to $24.3 million in 2023, then fell by 5.28% to $23.0 million in 2024, then jumped by 34.15% to $30.9 million in 2025, then retreated by 5.94% to $29.0 million in 2026.
- The last three Share-based Compensation figures came in at $29.0 million (Q2 2026), $20.1 million (Q1 2026), and $30.9 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 26.47 Mn |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | 29.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 29.05 Mn |
| Apr 3, 2026 | 29.05 Mn |
| Jan 2, 2026 | 20.10 Mn |
| Jan 2, 2026 | 20.10 Mn |
| Oct 3, 2025 | 30.89 Mn |
| Oct 3, 2025 | 30.89 Mn |
| Jul 4, 2025 | 36.07 Mn |
| Jul 4, 2025 | 36.07 Mn |
| Apr 4, 2025 | 25.93 Mn |
| Apr 4, 2025 | 25.93 Mn |
| Jan 3, 2025 | 26.35 Mn |
| Jan 3, 2025 | 26.35 Mn |
| Sep 27, 2024 | 23.02 Mn |
| Sep 27, 2024 | 23.02 Mn |
| Jun 28, 2024 | 25.35 Mn |
| Jun 28, 2024 | 25.35 Mn |
| Mar 29, 2024 | 19.11 Mn |
| Mar 29, 2024 | 19.11 Mn |
| Dec 29, 2023 | 24.31 Mn |
| Dec 29, 2023 | 24.31 Mn |